Shenzhen Neptunus Interlong Bio-technique Company Limited

SEHK:8329 Stock Report

Market Cap: HK$233.2m

Shenzhen Neptunus Interlong Bio-technique Valuation

Is 8329 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 8329 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 8329 (HK$0.14) is trading below our estimate of fair value (HK$3.99)

Significantly Below Fair Value: 8329 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 8329?

Key metric: As 8329 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 8329. This is calculated by dividing 8329's market cap by their current earnings.
What is 8329's PE Ratio?
PE Ratio6.8x
EarningsCN¥32.15m
Market CapCN¥217.10m

Price to Earnings Ratio vs Peers

How does 8329's PE Ratio compare to its peers?

The above table shows the PE ratio for 8329 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average10.6x
1643 Modern Chinese Medicine Group
18.3xn/aHK$249.0m
503 Lansen Pharmaceutical Holdings
13xn/aHK$750.6m
8049 Jilin Province Huinan Changlong Bio-pharmacy
4.2xn/aHK$767.5m
3737 Zhongzhi Pharmaceutical Holdings
6.9xn/aHK$820.4m
8329 Shenzhen Neptunus Interlong Bio-technique
6.8xn/aHK$233.2m

Price-To-Earnings vs Peers: 8329 is good value based on its Price-To-Earnings Ratio (6.8x) compared to the peer average (10x).

Price to Earnings Ratio vs Industry

How does 8329's PE Ratio compare vs other companies in the HK Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
8329 6.8xIndustry Avg. 8.0xNo. of Companies6PE0612182430+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 8329 is good value based on its Price-To-Earnings Ratio (6.8x) compared to the Hong Kong Pharmaceuticals industry average (8x).

Price to Earnings Ratio vs Fair Ratio

What is 8329's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

8329 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio6.8x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 8329's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Consun Pharmaceutical Group

HK$6.8b

Researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China.

1681

HK$8.22

7D

-2.1%

1Y

74.9%

Innovent Biologics

HK$60.6b

A biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People’s Republic of China.

1801

HK$37.00

7D

-0.5%

1Y

-15.4%

China Shineway Pharmaceutical Group

HK$6.1b

An investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People’s Republic of China and Hong Kong.

2877

HK$8.13

7D

-3.3%

1Y

n/a